Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Mirabella Financial Services LLP

Mirabella Financial Services LLP lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 83.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,447 shares of the biopharmaceutical company’s stock after purchasing an additional 2,477 shares during the period. Mirabella Financial Services LLP’s holdings in Alnylam Pharmaceuticals were worth $2,479,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $27,000. Ameriflex Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $32,000. ORG Partners LLC grew its stake in Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $36,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ALNY shares. HC Wainwright reissued a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Leerink Partners lowered their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Truist Financial decreased their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $468.84.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $7,874,697.12. This trade represents a 9.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the transaction, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. Insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.8%

Alnylam Pharmaceuticals stock opened at $318.91 on Tuesday. The company has a market capitalization of $42.29 billion, a PE ratio of 186.50 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a 50 day moving average price of $342.78 and a 200 day moving average price of $408.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the company earned ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.